Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
PODD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$173.00 - $329.33
Previous CloseN/A
Volume86.50K
Average Volume (3M)896.81K
Market Cap
$21.94B
Enterprise Value$22.30B
Total Cash (Recent Filing)$953.40M
Total Debt (Recent Filing)$1.39B
Price to Earnings (P/E)56.1
Beta1.10
Next Earnings
Aug 07, 2025EPS Estimate
0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.02
Shares Outstanding70,374,920
10 Day Avg. Volume695,223
30 Day Avg. Volume896,814
Financial Highlights & Ratios
PEG Ratio-79.34
Price to Book (P/B)17.99
Price to Sales (P/S)0.00
P/FCF Ratio72.14
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue3.03
Enterprise Value/Gross Profit15.36
Enterprise Value/Ebitda13.62
Forecast
1Y Price Target
$338.39Price Target Upside8.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Insulet News
Bulls Say, Bears Say
Bulls Say
Financial PerformancePODD reported a gross margin of 71.9%, which was 210 basis points above consensus, primarily due to improved manufacturing and supply chain efficiencies.
Market PositionInsulet remains in the pole position as the pump market is on the steep part of the adoption curve by insulin-intensive diabetics.
Product DifferentiationAnalyst views PODD as a top idea for robust growth driven by product differentiation and new indications.
Bears Say
Competitive PricingAnalyst believes PODD's premium trading price reflects its durable competitive edge, high growth rate, and meaningful margin expansion, which might face challenges if competitors adjust pricing strategies.
Market DynamicsPODD remains well positioned against a backdrop of favorable dynamics, but shifts in market trends could impact its increasing profitability.
Sales ChallengesPODD's sales force expansion, crucial for increasing direct sales reach, indicates potential challenges in fully penetrating the market.
Ownership Overview
0.37% Insiders
40.70% Mutual Funds
29.04% Other Institutional Investors
3.12% Public Companies and Individual Investors
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $173.00 and its highest was $329.33 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $21.94B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Aug 07, 2025 which is in 60 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on May 08, 2025. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.23.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 0.93.
How many shares outstanding does Insulet have?
Insulet has 70,374,920 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.02 in its last earnings report, beating expectations of $0.79. Following the earnings report the stock price went up 20.883%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
Insulet Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$338.39 (8.54% Upside)
$338.39 (8.54% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 571.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.02%
12-Months-Change
Fundamentals
Return on Equity
37.92%
Trailing 12-Months
Asset Growth
34.04%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD Company Deck
PODD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant revenue and gross margin growth. The company's expansion into the type 2 diabetes market and international markets is progressing well. While there are some challenges related to tariffs and increased interest expenses, these are being effectively managed. Overall, the company's positive achievements and strategic growth plans outweigh the lowlights.Read More>PODD Revenue Breakdown
74.73% U.S.
25.27% International
PODD Stock 12 Month Forecast
Average Price Target
$338.39
▲(8.54%Upside)